INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Dun & Bradstreet Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines

Pomerantz LLP announced a securities class action against former Dun & Bradstreet shareholders over the company's $9.15-per-share cash acquisition by Clearlake Capital, which closed August 26, 2025. The complaint alleges that merger disclosures misrepresented the sale process and company value, omitted Bank of America valuations of potentially superior alternatives, and failed to disclose Executive Chairman William P. Foley II's alleged conflicts and advisor ties. Investors who acquired DNB during the class period have until November 10, 2026, to seek appointment as lead plaintiff.

Analysis

There is no direct public-equity exposure to DNB following the completed cash acquisition, so this filing is not a standalone tradable catalyst. The relevant market mechanism is contingent liability and reputational risk for transaction advisers: BAC could face discovery costs, headline risk, or a settlement contribution only if allegations establish a materially deficient fairness process or conflicted advisory relationship. For a bank of BAC's scale, even a sizeable deal-specific outcome is immaterial to earnings and capital; the more important risk is precedent if similar challenges broaden scrutiny of sell-side valuation disclosures.

Over the next days to 1-3 months, BAC shares should not materially respond absent a court ruling, amended complaint with concrete internal communications, regulatory inquiry, or identification of damages that implicates the adviser. The November lead-plaintiff deadline is procedural rather than an economic catalyst. A 6-18 month risk exists only if discovery surfaces evidence that advisory analyses were knowingly incomplete or that conflicts impaired the process; that could modestly raise litigation reserves and pressure advisory-franchise perception, but remains low probability.

The contrarian view is that merger-objection litigation after a closed transaction is often economically settled rather than adjudicated, and law-firm announcements are not independent evidence of liability. Any BAC weakness attributable solely to this release would likely be noise. Monitor docket developments, BAC's legal-reserve disclosures, and whether the complaint survives a motion to dismiss before assigning valuation significance.

Key Decisions for Investors

• No directional BAC trade on this announcement; expected earnings and CET1 impact is de minimis absent a regulatory action or a discovery-driven escalation.
• Set an event alert for dismissal rulings, an amended complaint naming specific adviser conduct, or any SEC/DOJ inquiry; reassess only if those developments coincide with an increase in BAC litigation reserves or advisory-fee guidance pressure.
• If BAC underperforms the BKX by more than 2% on litigation headlines alone, consider a 1-3 month mean-reversion long BAC versus short KBE, with thesis invalidated by a formal regulatory investigation or disclosed reserve increase.
• For merger-arbitrage and governance screens, treat the case as a reminder to discount announced-deal process quality where management has accelerated-sale incentives and adviser conflicts; it does not create a current DNB security to trade.